← Back to Screener
Natural Alternatives International Inc. (NAII)
Price$2.52
Value ScoreA
Growth ScoreC
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-33.99%
Price vs S&P 500 (4W)-11.59%
VGM Score59.13
Market Capitalization$16.00M
All Metrics
P/CF (Annual)2.70x
Book Value / Share (Quarterly)$10.06
P/TBV (Annual)2.41x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-8.77%
Cash Flow / Share (Quarterly)$-1.44
Price vs S&P 500 (YTD)-39.98%
Gross Margin (TTM)7.62%
Net Profit Margin (TTM)-10.13%
EPS (TTM)$-2.39
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-2.39
Revenue Growth (5Y)1.78%
EPS (Annual)$-2.28
ROI (Annual)-17.13%
Gross Margin (Annual)7.15%
Net Profit Margin (5Y Avg)-0.57%
Cash / Share (Quarterly)$1.47
Revenue Growth QoQ (YoY)23.35%
ROA (Last FY)-8.93%
Revenue Growth TTM (YoY)13.06%
EBITD / Share (TTM)$-0.47
ROE (5Y Avg)-0.04%
Operating Margin (TTM)-5.30%
Cash Flow / Share (Annual)$0.38
P/B Ratio0.25x
P/B Ratio (Quarterly)0.26x
Net Income / Employee (Annual)$-46,300
EV / Revenue (TTM)0.18x
Net Interest Coverage (TTM)-4.15x
ROA (TTM)-9.32%
EV / EBITDA (TTM)14.14x
EPS Incl Extra (Annual)$-2.28
Current Ratio (Annual)2.06x
Quick Ratio (Quarterly)0.76x
3-Month Avg Trading Volume0.02M
52-Week Price Return-23.25%
EV / Free Cash Flow (Annual)11.01x
Revenue / Employee (TTM)$484,200
Tangible BV / Share (Quarterly)$3.79
P/S Ratio (Annual)0.12x
Asset Turnover (Annual)0.85x
52-Week High$4.96
Operating Margin (5Y Avg)0.91%
EPS Excl Extra (Annual)$-2.28
CapEx CAGR (5Y)-4.46%
Tangible BV CAGR (5Y)5.40%
26-Week Price Return-18.06%
Quick Ratio (Annual)0.96x
13-Week Price Return-7.97%
Total Debt / Equity (Annual)0.16x
Current Ratio (Quarterly)1.64x
Enterprise Value$25.51M
Revenue / Share Growth (5Y)4.24%
Asset Turnover (TTM)0.92x
Book Value / Share Growth (5Y)1.07%
Revenue / Employee (Annual)$443,200
Inventory Turnover (Annual)4.91x
Pretax Margin (Annual)-8.27%
Cash / Share (Annual)$1.99
3-Month Return Std Dev42.29%
Gross Margin (5Y Avg)11.97%
Net Income / Employee (TTM)$-49,000
ROE (Last FY)-19.84%
Net Interest Coverage (Annual)-3.73x
EPS Basic Excl Extra (Annual)$-2.28
P/FCF (TTM)4.86x
Receivables Turnover (TTM)8.80x
Total Debt / Equity (Quarterly)0.30x
EPS Incl Extra (TTM)$-2.39
Receivables Turnover (Annual)8.24x
ROI (TTM)-17.80%
P/S Ratio (TTM)0.11x
Pretax Margin (5Y Avg)0.11%
Revenue / Share (Annual)$21.84
Tangible BV / Share (Annual)$4.42
Price vs S&P 500 (52W)-51.46%
Year-to-Date Return-29.05%
5-Day Price Return-0.39%
EPS Normalized (Annual)$-2.28
ROA (5Y Avg)0.96%
Net Profit Margin (Annual)-10.45%
Month-to-Date Return-4.87%
Cash Flow / Share (TTM)$0.89
EBITD / Share (Annual)$-0.69
Operating Margin (Annual)-6.67%
LT Debt / Equity (Annual)0.13x
ROI (5Y Avg)0.44%
LT Debt / Equity (Quarterly)0.13x
EPS Basic Excl Extra (TTM)$-2.39
P/TBV (Quarterly)2.37x
P/B Ratio (Annual)0.30x
Inventory Turnover (TTM)4.60x
Pretax Margin (TTM)-6.76%
Book Value / Share (Annual)$11.08
Price vs S&P 500 (13W)-17.72%
Beta0.36x
P/FCF (Annual)6.90x
Revenue / Share (TTM)$23.55
ROE (TTM)-21.48%
52-Week Low$2.33
vGradeA
gGradeC
mGradeD
vgmGradeC
Show chart for
Industry Peers — Pharmaceutical Preparations(17)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NAIINatural Alternatives International Inc. | A | C | D | $2.52 |
| DFTXDefinium Therapeutics, Inc. Common Shares | — | — | A | $24.06 |
| CRONCronos Group Inc. Common Share | C | B | B | $2.82 |
| TLRYTilray Brands, Inc. Common Stock | B | B | D | $5.49 |
| CGCCanopy Growth Corporation Common Shares | B | D | D | $1.08 |
| USNAUSANA Health Sciences Inc | B | D | D | $18.33 |
| NAGENiagen Bioscience, Inc. Common Stock | C | B | D | $3.61 |
| SNDLSundial Growers Inc. Common Shares | A | C | C | $1.46 |
| ACBAurora Cannabis Inc. Common Shares | B | D | D | $3.64 |
| MDWDMediWound Ltd. | D | F | D | $13.82 |
| FTLFFitLife Brands, Inc. Common Stock | B | C | D | $9.91 |
About
Natural Alternatives International is a nutritional supplement and healthcare product manufacturer serving U.S. and international markets through contract manufacturing and licensing. Its Private-Label Contract Manufacturing segment, the primary revenue driver, manufactures supplements and healthcare products for third-party distributors. The company also generates royalty income through patent and trademark licensing agreements.